CYP4A11 and CYP4F2 Gene Variants as Makers of Cardiovascular Adverse Events of Non-steroidal Anti-inflammatory Drugs
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
Randomized, double-blinded, cross-over and placebo controlled clinical trial to evaluate the
association between genetic polymorphism of CYP4F2 with cardiovascular adverse effects of
non-steroidal anti-inflammatory drugs (NSAIDs). Two groups were included according the CYP4F2
V433M genetic polymorphism (control - MM, N=7 vs. VV or VM variants, N=13). According the
sample size planned, a mean difference of total body water delta between groups (control vs.
polymorphic) of at least allow 10% could be observed.